Clinical trials: Vaccine Prophylaxis
MERS (Middle East Respiratory Syndrome), MERS
Study of Safety and Immunogenicity of BVRS-GamVac
The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 during the first Middle East respiratory syndrome (MERS) outbreak.
- Trial name
- NCT04130594
- Testing
- BVRS-GamVac
- Where
- Russia
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention
A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older
The purpose of this study is to evaluate the immunogenicity and safety of Ad26.RSV.preF-based vaccine and quadrivalent high-dose seasonal influenza vaccine when administered either concomitantly or separately.
- Trial name
- NCT05071313
- Testing
- Ad26.RSV.preF-based vaccine, Quadrivalent High-dose Influenza Vaccine
- Where
- 19 sites in United States
- Volunteers
- 777 people
- Sponsor
- Janssen Vaccines & Prevention B.V.
Covid19
Study of the EpiVacCorona Vaccine With the Involvement of Volunteers Aged 60 Years and Above
The aim of the clinical study is to study the safety, reactogenicity and immunogenicity indicators of the EpiVacCorona vaccine, with the involvement of volunteers aged 60 years and above.
- Trial name
- NCT05021016
- Testing
- EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)
- Where
- Russia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"
HIV Seronegativity, HIV Infections
Screening Protocol for HIV Vaccine Studies
Healthy volunteers will be screened under this protocol for possible participation in a study testing a vaccine against HIV, the virus that causes AIDS. Healthy adults 18 to 60 years of age may be eligible for this study.
- Trial name
- NCT00031304
- Where
- United States
- Volunteers
- 1,324 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV-2
GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)
This clinical trial will evaluate the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-CoV-2(COVID-19) in healthy volunteers.
- Trial name
- NCT04673149
- Testing
- GLS-5310
- Where
- South Korea
- Volunteers
- 171 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
Papilloma Viral Infection
A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)
Primary objective To demonstrate that administration of V503 induces non-inferior Geometric Mean Titres (GMTs) for serum anti-HPV 6, 11, 16, and 18, compared to GARDASIL in 16- to 26-year-old men
- Trial name
- NCT02114385
- Testing
- V503, GARDASIL
- Where
- 7 sites in Belgium, Germany and 1 more
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Prophylaxis of Lyme Borreliosis
Phase 1/2 Lyme Vaccine Study
Section 1: The purpose of the study is to obtain safety and immunogenicity data of different dose levels of a multivalent recombinant OspA Lyme Borreliosis (mv rOspA LB) Vaccine with and without adjuvant in seronegative healthy…
- Trial name
- NCT01504347
- Testing
- Multivalent recombinant OspA Lyme Borreliosis Vaccine
- Where
- 8 sites in Austria, Germany
- Volunteers
- 1,630 people, healthy volunteers welcome
- Sponsor
- Baxalta now part of Shire
Meningococcal Disease
One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age
One year antibody persistence after the fourth dose boost or two catch-up doses administered starting from 12 months of age and to evaluate the response to a a third dose boost or two catch-up dose starting at 24 months of age.
- Trial name
- NCT01139021
- Testing
- rMenB+OMV NZ
- Where
- 19 sites in Czechia, Finland
- Volunteers
- 508 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Cytomegalovirus Infections, Preventation of Cytomegalovirus Reactivation
Evaluate Tolerability and Safety of BD03 for Prevention of CMV and BKV Reactivation in Kidney Transplant Recipient
This study is a phase I, open-label study to determine recommended phase 2 dose (RP2D) for the BD03 vaccination in kidney transplant recipients.
- Conditions
- Cytomegalovirus Infections, Preventation of Cytomegalovirus Reactivation, BK Virus Infection, Preventation of BK Virus Reactivation
- Trial name
- NCT03576014
- Testing
- BD03
- Where
- 2 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- SL VAXiGEN
Bladder Cancer
Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer
The purpose of this study is to evaluate the clinical efficacy for the prevention of the recurrence for bladder cancer after TUR-Bt
- Trial name
- NCT00633204
- Testing
- MPHOSPH1 and DEPDC1
- Where
- Japan
- Volunteers
- 150 people
- Sponsor
- Iwate Medical University
Tuberculosis, Pulmonary
Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence
This is a phase 2, double-blind, randomized (1:1), placebo-controlled trial with two parallel groups. H56:IC31 (investigational vaccine) Placebo 900 HIV-negative adults with a diagnosis of drug susceptible pulmonary TB are…
- Trial name
- NCT03512249
- Testing
- H56:IC31
- Where
- 6 sites in South Africa, Tanzania
- Volunteers
- 831 people
- Sponsor
- International AIDS Vaccine Initiative
Anthrax
VELOCITY: An Anthrax Vaccine Clinical Study
This study is designed to evaluate the lot consistency (using three consecutively manufactured lots), safety, and ability of the AV7909 anthrax vaccine to generate an immune response in healthy adults and compare the response to…
- Trial name
- NCT03877926
- Testing
- AV7909, BioThrax
- Where
- 35 sites in United States
- Volunteers
- 3,689 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Healthy
A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus
This is a Phase I, parallel design open label study to evaluate safety, tolerability and immunogenicity of nine different formulation of two individual H1 and one H5 HA plasmid administered intradermally followed by…
- Trial name
- NCT01405885
- Testing
- INO-3605, INO-3609, INO-3401
- Where
- 3 sites in United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Inovio Pharmaceuticals
Influenza, Healthy
Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season
This prospective annual release study is designed to evaluate the safety of 3 new influenza virus vaccine strains to be included in FluMist Quadrivalent for the 2015-2016 influenza season
- Trial name
- FluMist (NCT02473510)
- Testing
- Trivalent Influenza Vaccine
- Where
- 3 sites in United States
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Meningococcal Disease
Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months
The purpose of this study is to evaluate how well the immuno response against meningococcal serogroups A, C, W and Y lasts in children who were vaccinated with MenACWY as infants.
- Trial name
- NCT00601731
- Testing
- MenACWY-CRM197, Blood test
- Where
- 3 sites in Canada, United Kingdom
- Volunteers
- 382 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Rabies
Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents
The aim of this study is to evaluate the safety of the monoclonal antibody cocktail CL184 in combination with rabies vaccine compared with human rabies immune globulin (HRIG) in combination with rabies vaccine in healthy children…
- Trial name
- NCT00708084
- Testing
- CL184, HRIG
- Where
- Philippines
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Novel 2009 Influenza H1N1, Influenza, Human
Tolerability and Immunogenicity Study of FLUVAL P H1N1 Flu Vaccine of Omninvest in Children and Adolescents
This is a single-blind, reference drug controlled study to assess safety and tolerability of FLUVAL P H1N1 monovalent influenza vaccine (whole virus, inactivated, adjuvanted with alumn phosphate gel) containing 6 mcgHA per 0.5mL…
- Trial name
- NCT01407978
- Testing
- Vaccination with Fluval P monovalent influenza vaccine, Vaccination with Fluval AB, Vaccination with Fluval AB Novo
- Where
- Hungary
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza
A Study to Evaluate Safety and Immunogenicity of FluvalAB-like Influenza Vaccine in Non-Elderly Adult and Elderly Subjects
The purpose of this study is to determine the immunogenicity and tolerability of one 0.5 mL intramuscular (IM) injection of FLUVAL AB-like trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza…
- Trial name
- NCT01459276
- Testing
- Vaccination with FAB-6011, Vaccination with FluvalAB
- Where
- 7 sites in Hungary
- Volunteers
- 1,206 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza, Healthy
Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
This prospective annual release study is designed to evaluate the safety on new influenza virus vaccine strains to be included in FluMist Quadrivalent for the 2013-2014 influenza season.
- Trial name
- NCT01859143
- Testing
- Trivalent Influenza Vaccine
- Where
- 3 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Rabies, Prevention
A Study to Evaluate a PIKA Rabies Vaccine（Vero Cell）for Human Use,Freeze-dried
This is a phase III, randomized, comparator-controlled, double-blind, multicenter study to evaluate lot-to-lot consistency of three lots of a PIKA Rabies Vaccine, immunogenicity and safety in healthy adults using a post-exposure…
- Trial name
- NCT05667974
- Testing
- PIKA Rabies Vaccine (Vero Cell) for Human use, Freeze-dried, Chirorab
- Where
- 7 sites in Pakistan, Philippines
- Volunteers
- 4,500 people, healthy volunteers welcome
- Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.